The analyst rating from Morgan Stanley is based on several key factors regarding China's biotech sector. They note that the sector is at a turning point with stabilizing fundamentals, a resilient innovation base, ongoing licensing transactions, and a recovery in financing activities. However, in the first half of 2026 (1H26), the market is expected to experience limited high-conviction investment themes and unstable risk appetite due to a lack of catalysts and increasing geopolitical uncertainties.
Morgan Stanley anticipates that the biotech sector will face allocation pressure and range-bound fluctuations in 1H26, but they expect that catalysts, capital reallocation, and more favorable valuations will set the stage for clearer stock price direction in the second half of 2026 (2H26). They believe that the next growth phase will begin with meaningful data releases and increased visibility in business development and licensing transactions, which are expected to occur in 2H26.
As a result, Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, indicating their positive outlook for the stock in light of these anticipated developments.
